Global Pain Therapeutics Market and Modality Trends

Understand the Evolving Global Pain Therapeutics Market

Pain management remains one of the largest and most complex therapeutic areas. However, innovation has been limited, and the market continues to rely heavily on legacy drug classes.

This report helps you understand how the global pain therapeutics market is evolving. It explores current treatment paradigms, emerging modalities, and shifts in clinical practice.

Moreover, it highlights how the industry is transitioning from opioid dependence toward safer, targeted therapies.

Report Value Proposition – What This Means for You

This report goes beyond market sizing. It helps you interpret what changes in pain therapeutics mean for your business.

You can use it to:

• Identify high-potential targets such as NaV1.7 and NaV1.8 inhibitors
• Evaluate pipeline diversity across molecule types and modalities
• Benchmark against global leaders in pain therapeutics
• Support licensing, R&D prioritisation, and portfolio strategy
• Understand physician perceptions and unmet clinical needs

In addition, the insights combine primary research from physicians and key opinion leaders with GlobalData’s proprietary analysis. They are trusted by Fortune 500 companies and leading healthcare organisations.

Key Market Insights – Opioid Dependence, Generics and Innovation Gaps

The report provides a clear view of current market realities:

• The market is dominated by NSAIDs and opioids
• Generics account for ~98% of all marketed pain drugs globally
• There are 391 innovator drugs currently marketed
• Innovation remains limited, with focus on reformulations and delivery systems

However, this dynamic is beginning to shift. Therefore, new therapeutic approaches are gaining attention.

Emerging Trends – NaV Inhibitors and Next-Generation Pain Therapies

One of the most significant R&D shifts is the emergence of voltage-gated sodium channel inhibitors.

Targets such as NaV1.7 and NaV1.8 are gaining traction as promising approaches for non-addictive pain relief.

In addition:

• Pipeline diversity is increasing across targets and modalities
• Non-opioid and non-addictive therapies are a key focus
• Novel mechanisms such as cannabinoid receptor agonists and TRPV1 modulators are being explored

As a result, the future of pain management may move toward more targeted and safer therapies.

Scope

What You Will Learn

The report provides a comprehensive and structured view of the pain therapeutics landscape:

• Marketed products by class, indication, and molecular target
• Pipeline analysis by phase, molecule type, and route of administration
• Clinical trial trends and design challenges
• Physician perspectives and KOL insights
• Market size, segmentation, and forecast
• Key unmet needs, including non-addictive therapies
• Strategic opportunities and barriers

In addition, it highlights evolving regulatory and clinical considerations.

Target Buyers for This Report

This report is designed for decision-makers across healthcare:

• Heads of R&D and Innovation
• Business Development and Licensing Teams
• Portfolio Strategy Leaders
• Healthcare Investors and Analysts
• Market Intelligence and Competitive Strategy Teams
• Commercial and Marketing Leaders

If you are responsible for growth, pipeline strategy, or investment decisions, this report can support your priorities.

How Companies Use This Report

Organizations across the healthcare ecosystem can apply these insights in practical ways:

• Pharmaceutical companies: Identify licensing opportunities and prioritise pipeline investments
• Biotech firms: Evaluate novel targets and optimise clinical development strategies
• Investors and private equity firms: Assess high-growth segments and emerging players
• Healthcare providers: Understand evolving treatment approaches and prescribing trends
• Commercial teams: Align go-to-market strategies with physician preferences and unmet needs

For example, companies like Pfizer may assess portfolio diversification, while Johnson & Johnson may evaluate innovation in non-opioid pain solutions.

Key Highlights

Neuropathic Pain Leads While Nociceptive Pain Drives Growth

The report highlights important segmentation trends:

• Neuropathic pain is the largest segment, valued at ~$4.1 billion
• Development efforts are heavily focused on neuropathic indications
• Nociceptive pain is expected to see the fastest growth through 2031

Therefore, understanding indication-level dynamics is critical for strategic planning.

Reasons to Buy

Benchmark Against Global Leaders in Pain Therapeutics

Understanding competitive positioning is essential. Therefore, this report profiles key players shaping the market:

• Vertex Pharmaceuticals Inc
• Eli Lilly and Co
• Grunenthal GmbH
• Jiangsu Hengrui Pharmaceuticals Co Ltd
• Tonix Pharmaceuticals Inc
• Haleon Plc

You can benchmark pipelines, innovation focus, and strategic positioning across these players. This may help you identify competitive gaps and partnership opportunities.

Built on Trusted Data and Clinical Insight

This report is backed by GlobalData’s robust healthcare research capabilities:

• Built on proprietary datasets and market models
• Informed by primary research with physicians and KOLs
• Developed by analysts with deep therapeutic area expertise

Therefore, you can rely on the insights to support high-impact decisions.

Act Now to Stay Ahead in Pain Therapeutics Innovation

The pain therapeutics market is at an inflection point. However, unmet needs remain significant, and competition is evolving. This report helps you understand where innovation is happening and how the competitive landscape is shifting.

Therefore, if you are evaluating opportunities in non-opioid therapies, NaV inhibitors, or pipeline investments, now is the time to act.